Long-acting injectable aripiprazole: How might it fit in our tool box?

Clinical Schizophrenia and Related Psychoses

Volumn 7, Issue 2, 2013, Pages 87-92

  Gopalakrishna, Ganesh ^a   Aggarwal, Arpit ^a   Lauriello, John ^a  

^a University of Missouri   (United States)

Author keywords

Antipsychotics; Aripiprazole; LAI; Long acting injectable; Maintenance; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE; STERILE WATER;

AKATHISIA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; INJECTION PAIN; INJECTION SITE INDURATION; INJECTION SITE PAIN; LENGTH OF STAY; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORTALITY; PARKINSONISM; QT PROLONGATION; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREMOR; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; HUMANS; INJECTIONS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 84880681923     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.GOAG.043013     Document Type: Review

References (36)

1. McEvoy JP. The costs of schizophrenia. J Clin Psychiatry 2007;68(Suppl 14):4-7.
2. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24(1):75-85.
3. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17(2):325-351.
4. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-351.
5. Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database Syst Rev 2007(1):CD006329.
6. Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002;53(1-2):145-159.
7. Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, Von Wilmsdorff M, et al. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2011;72(2):205-218.
8. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52(3):173-188.
9. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012;5:CD008016.
10. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55(8):886-891.
11. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30(3):437-452.
12. Haddad PM, Lambert T, Lauriello J, editors. Antipsychotic long-acting injections. New York: Oxford University Press; 2011.
13. Abilify Maintena [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd.; 2013. Available from: http://www.otsuka-us.com/Products/Documents/ Abilify. M. PI.pdf.
14. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168(6):603-609.
15. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Longacting risperidone and oral antipsychotics in unstable schizophrenia. NEJM 2011;364(9):842-851.
16. Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985;10(4):315-333.
17. Risperidal Consta [package insert]. Titusville, NJ: Janssen Pharmaceuticals Ltd.; 2011. Available from: http://www.janssencns.com/shared/pi/ risperdal/risperdalconsta.pdf.
18. Moller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007;67(11):1541-1566.
19. Zyprexa Relprevv [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011. Available from: http://pi.lilly.com/us/zyprexa-relprevv.pdf.
20. Detke HC, Zhao F, Garhyan P, Carlson J, McDonnell D. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol 2011;26(1):35-42.
21. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69(5):790-799.
22. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167(2):181-189.
23. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010;10:43.
24. Citrome L. Paliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010;64(2):216-239.
25. Invega Sustenna [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2012. Available from: http://www.janssencns.com/sustenna- prescribinginformation.
26. Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs 2007;16(6):771-775.
27. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001;62(12):923-924.
28. Rivas-Vazquez RA. Aripiprazole: a novel antipsychotic with dopamine stabilizing properties. Professional Psychology: Research and Practice 2003;34(1):108-111.
29. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41.
30. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-771.
31. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in shortterm, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-136.
32. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Clin Psychiatry 2003;64(9):1048-1056.
33. Park MH, Han C, Pae CU, Lee SJ, Patkar AA, Masand PS, et al. Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert Rev Neurother 2011;11(11):1541-1552.
34. Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73(5):617-624.
35. Fleischhacker WW, Sanchez R, McQuade R, Carson W, Forbes RA, Walling D, et al. Pharmacokinetic study of once-monthly aripiprazole extended-release injectable suspension in adult patients with schizophrenia. 164th Annual Meeting of the American Psychiatric Association 14-18 May 2011; Honolulu, Hawaii.
36. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short-and long-term aripiprazole trials. J Psychopharmacol 2010;24(7):1019-1029.